Search Results
May 19, 2026, 09:00 ET Three TriKE Candidates In Clinic As NK Cell Engager Field Reorganizes
adjacent — but architecturally distinct — corner of the NK cell therapy universe from GT Biopharma's engager-platform approach. Nkarta's progression of NKX019 and related programs into pivotal-stage clinical work has helped to establish the CAR-NK reference comparable on which much of the broader public-market
More news about: Equity Insider
Mar 10, 2026, 17:31 ET CD19 Inhibitors Market to Witness Significant Expansion During the Forecast Period (2025-2034) as Autoimmune and Oncology Pipelines Accelerate | DelveInsight
investigational drugs such as Obexelimab (Zenas BioPharma), GLPG5101 (Galapagos NV), IKS 03 (Iksuda Therapeutics), ANKTIVA + CD19 t-haNK (ImmunityBio), NKX019 (Nkarta), CABA-201 (Cabaletta Bio), CLN-978 (Cullinan Therapeutics), ATA3219 (Atara Bio), KITE-363, KITE-753, KITE-197, and KITE-363 (Gilead), PL001
More news about: DelveInsight Business Research, LLP
Oct 22, 2025, 17:31 ET Glomerulonephritis Market Projected to Surge by 2034 with Rising Demand for Targeted Therapies | DelveInsight
of emerging therapies such as lixudebart (Alentis Therapeutics), mezagitamab (Takeda Pharmaceutical), felzartamab (CD38) (Biogen), LNP023 (Novartis), NKX019 (Nkarta), and others will further propel the market. LAS
More news about: DelveInsight Business Research, LLP